Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001913593 | SCV002186643 | uncertain significance | DOCK2 deficiency | 2021-08-14 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with methionine at codon 1360 of the DOCK2 protein (p.Val1360Met). The valine residue is moderately conserved and there is a small physicochemical difference between valine and methionine. This variant is present in population databases (rs137922056, ExAC 0.05%). This variant has not been reported in the literature in individuals affected with DOCK2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002555752 | SCV003534599 | uncertain significance | Inborn genetic diseases | 2022-10-25 | criteria provided, single submitter | clinical testing | The c.4078G>A (p.V1360M) alteration is located in exon 41 (coding exon 41) of the DOCK2 gene. This alteration results from a G to A substitution at nucleotide position 4078, causing the valine (V) at amino acid position 1360 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |